Pyxis Oncology, Inc. (NASDAQ: PYXS)

Pyxis Oncology, Inc. (PYXS) is a company that operates in the biopharmaceutical industry, specifically focused on developing innovative therapies to combat difficult-to-treat cancers. The company was established in 2018 and began its operations in 2019. Pyxis Oncology is committed to building a pipeline of biological products, including antibody-drug conjugates (ADCs) and monoclonal antibody immunotherapies, that target the tumor microenvironment (TME).

Pyxis Oncology generates revenue through the development and commercialization of its product candidates, such as PYX-201 and PYX-106. These products are currently in the clinical trial stage and are designed to target specific aspects of the tumor microenvironment. PYX-201 is an investigational ADC that consists of human IgG1, site-specifically conjugated with a next-generation auristatin derivative via proteases-cleavable linker. It targets Extradomain-B Fibronectin (EDB+FN) within the tumor stroma, which is crucial for blood vessel morphogenesis, providing the tumor with access to nutrition and oxygen, and a means to remove waste and metastasize. PYX-106, on the other hand, is an investigational fully human IgG1 Siglec-15-targeting antibody that blocks Siglec-15-mediated suppression of T-cell proliferation and function.

Pyxis Oncology's unique ADC platform, which includes site-specific conjugation chemistry and novel linkers, sets it apart from its competitors in the ADC and immunotherapy markets. The company's focus on targeting the TME, a novel approach in the treatment of cancer, further distinguishes it in the industry. Some of Pyxis Oncology's key competitors in these markets include Pfizer, Roche Holding AG, AstraZeneca plc, Merck & Co., Inc., and Bristol-Myers Squibb Company.

Pyxis Oncology's customer base includes patients with relapsed or refractory solid tumors, including non-small cell lung cancer, locally advanced/metastatic breast cancer, hormone receptor-positive and human epidermal growth factor receptor 2-positive and negative breast cancers, triple-negative breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, and kidney cancer.

In addition to its primary products, Pyxis Oncology has several preclinical programs under development. These include PYX-203, an investigational ADC targeting the interleukin-3 receptor, and PYX-102, an investigational immune-therapeutic targeting killer cell lectin-like receptor subfamily G member 1. The company has also acquired certain preclinical programs from Apexigen, including APX601, APX701, and APX801, which are designed to reverse immune suppression in the TME and unleash immune-mediated tumor killing activity.

Pyxis Oncology has a robust technology platform, including the FACT Platform, which utilizes preclinically optimized payloads and site-specific conjugation to develop next-generation ADCs with improved therapeutic index and bystander activity. The APXiMAB Platform is a proprietary antibody-discovery platform that enables the discovery of multiple protein therapeutic product candidates against a variety of molecular targets, including targets that are difficult to generate antibodies with conventional antibody technologies.

Pyxis Oncology has several out-license relationships and agreements, including a license agreement with the University of Chicago, a license agreement with Pfizer, a license agreement with Biosion, and a sublicense agreement with Toray Industries, Inc. These agreements provide the company with the opportunity to receive milestone payments and royalties on net sales of licensed products. Pyxis Oncology also has several patent applications and patents that cover its product candidates and proprietary technology, further protecting its innovative contributions to the field of oncology.